156 related articles for article (PubMed ID: 8993096)
1. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.
Heresco-Levy U; Silipo G; Javitt DC
Psychopharmacol Bull; 1996; 32(4):731-40. PubMed ID: 8993096
[TBL] [Abstract][Full Text] [Related]
2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
3. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
5. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
[TBL] [Abstract][Full Text] [Related]
6. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
7. Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain.
Long KD; Mastropaolo J; Rosse RB; Manaye KF; Deutsch SI
Brain Res Bull; 2006 May; 69(6):626-30. PubMed ID: 16716829
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of negative symptoms in schizophrenia by glycine.
Javitt DC; Zylberman I; Zukin SR; Heresco-Levy U; Lindenmayer JP
Am J Psychiatry; 1994 Aug; 151(8):1234-6. PubMed ID: 8037263
[TBL] [Abstract][Full Text] [Related]
9. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
10. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
11. The role of group I metabotropic glutamate receptors in schizophrenia.
Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
[TBL] [Abstract][Full Text] [Related]
12. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
13. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
14. Glycine modulators in schizophrenia.
Javitt DC
Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
[TBL] [Abstract][Full Text] [Related]
15. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
16. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine.
Arvanov VL; Wang RY
J Pharmacol Exp Ther; 1999 May; 289(2):1000-6. PubMed ID: 10215680
[TBL] [Abstract][Full Text] [Related]
17. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
20. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment].
Noda Y; Nabeshima T
Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
